PPLC 2021: Results of a study investigating zanubrutinib for treatment of relapsed B-cell lymphomas.
Home / Resource Library / Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor Intolerant B-Cell Malignancies
PPLC 2021: Results of a study investigating zanubrutinib for treatment of relapsed B-cell lymphomas.